Maciej Goniewicz

PhD, PharmD

Special Interests:

Tobacco control Nicotine pharmacology and pharmacokinetics Nicotine addiction pharmacotherapy and smoking cessation Toxicology and harm reduction

About Maciej Goniewicz

Biography:

Dr. Maciej L. Goniewicz joined the staff of Roswell Park Comprehensive Cancer Center (Roswell Park) in 2013 as Assistant Member of the Department of Health Behavior, Division of Cancer Prevention and Population Sciences. In 2016, he was appointed Associate Member.

He earned a Pharm.D. degree (2002) and a Ph.D. in Toxicology and Pharmacology (2007) from the Medical University of Silesia, Poland. He completed his postdoctoral fellowships in Clinical Pharmacology and Tobacco Control at the University of California San Francisco and in Smoking Cessation Treatment in Queen Mary University of London, UK. 

Dr. Goniewicz has authored over 40 scientific papers on topics related to tobacco control, biomarkers, and nicotine-containing products. His work has been published in Tobacco Control, Nicotine and Tobacco Research, Pediatrics, Atherosclerosis, Critical Care Medicine, Chemical Research in Toxicology, Journal of Analytical Toxicology, and Cancer Epidemiology, Biomarkers, and Prevention.

Positions

Roswell Park Comprehensive Cancer Center

  • Professor of Oncology
  • Department of Health Behavior
  • Director of Shared Resource, NicoTAR

Background

Education and Training:

  • 2007 - PhD - Medical University of Silesia, Poland
  • 2002 - PharmD - Medical University of Silesia, Poland

Residency:

  • 2002-2003 - Residency Training in Community Pharmacy

Fellowship:

  • 2008-2010 - Postdoctoral Fellow (Clinical Pharmacology, Experimental Therapeutics, & Tobacco Control) - University of California San Francisco
  • 2011-2013 - Research Fellow (Nicotine Dependence Treatment) - Queen Mary University of London, UK

Board Certification:

  • 2011 - General Pharmaceutical Council, UK
  • 2003 - Polish Pharmaceutical Chamber

Professional Memberships:

  • 2009-present - Society for Research on Nicotine and Tobacco
  • 2004-2006 - International Society of Exposure Analysis
  • 2002-present - Polish Pharmaceutical Society
  • 2001-present - Polish Chemical Society

Research

Research Overview:

Dr. Goniewicz’s primary research area is in nicotine pharmacology, with a focus on nicotine dependence and smoking cessation. He has research experience in smoking cessation behavioral treatment, pharmacotherapy, and pharmacokinetics in both clinical and community-based settings.

Dr. Goniewicz’s current research is focused on new nicotine-containing products and alternative forms of tobacco. He examines safety and efficacy of electronic nicotine delivery devices, commonly called e-cigarettes. These studies include the laboratory evaluation of the products, pharmacological and toxicological assessment, surveys among their users, and their potential application in harm reduction and smoking cessation. He also evaluates implementation of new tobacco control laws and role of community pharmacists in smoking cessation.

Effect of E-Liquid Flavor on Respiratory Symptoms in People Using Electronic Nicotine Delivery Systems
Learn More
Comparing Nicotine Delivery, Subjective Effects, and Sensory Experiences of Tobacco Users Using Oral Nicotine Products and Electronic Cigarettes [ZYN Study]
Learn More

Clinical Trials

Effect of E-Liquid Flavor on Respiratory Symptoms in People Using Electronic Nicotine Delivery Systems
Learn More
Comparing Nicotine Delivery, Subjective Effects, and Sensory Experiences of Tobacco Users Using Oral Nicotine Products and Electronic Cigarettes [ZYN Study]
Learn More
Do electronic cigarettes reduce respiratory and cardiovascular risk in smokers?  Quitting Smoking and E-Cigarettes — What to Know Study Finds High Levels of Nicotine In Popular E-Cigarettes

Featured on Cancer Talk

Do electronic cigarettes reduce respiratory and cardiovascular risk in smokers? 
Quitting Smoking and E-Cigarettes — What to Know
Study Finds High Levels of Nicotine In Popular E-Cigarettes

Publications

Full Publications list on PubMed
  • Kasza KA, Conway KP, Borek N, Sharma E, Goniewicz ML, Cummings KM, Taylor K, Pearson JL, Bansal-Travers M, Travers MJ, Kaufman AR, Green VR, Kwan J, Tworek C, Yang L, Pharris-Ciurej N, van Bemmel DM, Ambrose BK, Compton WM, Backinger CL, Hyland AJ. Tobacco product use by adults and youth in the United States in 2013/14. N Eng J Med. 2017;376:342-53.
  • Shahab L, Goniewicz ML, Blount B, Brown J, McNeill A, Alwis KU, Feng J, Wang L, West R. Nicotine, carcinogen and toxicant exposure in long-term e-cigarette and nicotine replacement therapy users: a cross-sectional study. Ann Int Med. 2017;166:390-400.
  • Goniewicz ML, Gawron J, Smith DM, Jacob P, Peng M, Benowitz N. Electronic cigarettes deliver similar levels of nicotine and reduce exposure to combustion toxicants after switching from tobacco cigarettes. Nicotine Tob Res. 2017;19:160-7.
  • Goniewicz ML, Knysak J, Gawron M, Sobczak A, Jablonska M, Rosik-Dulewska C, Prokopowicz A, Kurek J, Havel C, Jacob P, Benowitz N. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2014;23:133-9.
  • Benowitz N, Goniewicz ML. The regulatory challenges of electronic cigarettes. JAMA 2013;310:685-6.